Falsified Medicines: MHRA publishes Class 4 FMD Medicines Information
Recommendation
6/7 May 2026
Copenhagen, Denmark
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via WDA(H) 50340 HMS Wholesale Limited. This license has since then been terminated.
In a Falsified Medicines Directive (FMD) Alert published 19 March 2020, the MHRA says that "the products do appear to be genuine with legitimate batch numbers. These products are thought to have been stolen from the legitimate supply chain in early 2019 and reintroduced into the supply chain between May and August 2019. This means that the correct transport and storage conditions cannot be guaranteed and while unlikely, could impact their effectiveness."
Only the batch numbers mentioned in appendix 1 of the PDF are within the scope of this alert. You can download the document here.
Related GMP News
21.04.2026Implementation of GDP for Pharmaceutical Products in Hong Kong
21.04.2026China's NMPA: Guiding Opinions & Q&A on Standardising Modern Pharmaceutical Logistics
21.04.2026GMDP IWG Three-Year Work Plan: What's Planned for GDP?
21.04.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 2
25.03.2026What is Good Distribution Practice (GDP)?
24.03.2026What Requirements must a Responsible Person for GDP meet?